Advertisement
Organisation › Details
Anokion (Group)
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company's antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion's approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications. *
Start | 2014-05-05 splitoff before | |
Predecessor | EPFL (Ecole Polytechnique Fédérale de Lausanne) | |
Industry | drug development | |
Industry 2 | immuno modulatory compound (IMO) | |
Person | Geraghty, Deborah (Anokion 202210 CEO) | |
Person 2 | Hubbell, Jeffrey A. (Anokion 201701 Chairman + CSO + Academic Founder + Prof at Univ Chicago + before at EPFL) | |
Region | Ecublens VD | |
Country | Switzerland | |
Street | 1A Chemin de la Dent d’Oche EPFL Innovation Park-L | |
City | 1024 Ecublens VD | |
Tel | +41-21-693-7237 | |
Address record changed: 2022-10-29 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Anokion (Group)
- [1] Anokion S.A.. (10/18/22). "Press Release: Anokion Announces $35 Million Equity Investment from Pfizer". Cambridge, MA & Lausanne....
- [2] Anokion S.A.. (1/8/17). "Press Release: Anokion Announces Exclusive Strategic Collaboration with Celgene to Develop Novel Tolerance-inducing Therapeutics for Autoimmune Diseases". Lausanne & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top